Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Febantel is a veterinary anthelmintic drug belonging to the benzimidazole class, primarily used to treat gastrointestinal nematode infections in animals, especially dogs. It acts as a pro-drug that is metabolized in the liver to form fenbendazole and other active metabolites. The mechanism of action involves interference with microtubule formation in parasitic cells, inhibition of glucose uptake, and disruption of energy metabolism within parasites. Febantel is commonly included as one component in combination deworming products (such as Drontal Plus) for broad-spectrum control of roundworms, hookworms, whipworms, and tapeworms[3][6]. It is not recommended for use in pregnant animals or very young puppies[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Febantel.